Anteris Technologies Global Corp. CHESS Depositary Interest (AVR)
ASX ASX Primary Summary
Anteris Technologies Global Corp. CHESS Depositary Interest (AVR) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anteris Technologies Global Corp. CHESS Depositary Interest ever had a stock split?
Anteris Technologies Global Corp. CHESS Depositary Interest Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Wayne Geoffrey Paterson CEO | ASX Exchange | Q0425C102 CUSIP |
| AU Country | - Employees | 2 Mar 2007 Last Dividend | 27 Feb 2020 Last Split | 13 Dec 2024 IPO Date |
Overview
Anteris Technologies Ltd operates within the structural heart domain, focusing on the development, manufacture, and sale of groundbreaking cardiac solutions. Initially founded as Admedus Limited in 1999, the company underwent a significant rebranding to Anteris Technologies Ltd in May 2020, marking a new era of innovation and development in regenerative medicines and structural heart solutions. Based in Toowong, Australia, Anteris Technologies Ltd has established itself as a key player in the structural heart sector by focusing on regenerative tissue products and advanced cardiac treatment technologies.
Products and Services
- ADAPT
- DurAVR™
- Regenerative Medicine Research
Anteris Technologies Ltd manufactures and distributes ADAPT, a pioneering regenerative tissue product designed to enhance the body's own regenerative capabilities. This product is a cornerstone of the company's offerings, reflecting Anteris' commitment to advancing regenerative medicine and providing innovative solutions for structural heart conditions.
Another significant innovation by Anteris Technologies is DurAVR™, a 3D single-piece aortic valve specially created for the treatment of aortic stenosis. This product exemplifies the company's dedication to addressing some of the most challenging aspects of structural heart diseases through cutting-edge technology and design. DurAVR™ represents a significant advancement in cardiac care, promising improved outcomes for patients suffering from aortic stenosis.
In addition to its product portfolio, Anteris Technologies is deeply involved in the research and development of regenerative medicines. This area of focus underscores the company's holistic approach to cardiac care, seeking not only to treat existing conditions but also to explore innovative treatments that harness the body's natural healing processes. Through its commitment to regenerative medicine research, Anteris Technologies aims to pave the way for future breakthroughs in the treatment of structural heart diseases.
